Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

FRHC

Freedom Holding Corp

Feb 17 • 04:00PM ET

112.32

-4.08 -3.51 %

Financial • Financial Conglomerates • Kazakhstan • NASD

Peers: MS GS SCHW IBKR RJF AMTD LAZ EVR PIPR SF

| Held by: IWP IWR IWF VONG ONEQ VT IWB IYF ESML BBMC

Index	-	P/E	2850.76	EPS (ttm)	0.04	Insider Own	70.69%	Shs Outstand	61.18M	Perf Week	-8.06%
Market Cap	6.87B	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	17.94M	Perf Month	-10.92%
Enterprise Value	5.69B	PEG	-	EPS next Q	-	Inst Own	3.93%	Short Float	4.28%	Perf Quarter	-18.34%
Income	2.66M	P/S	3.57	EPS this Y	-	Inst Trans	11.35%	Short Ratio	7.90	Perf Half Y	-34.66%
Sales	1.93B	P/B	4.93	EPS next Y	-	ROA	0.02%	Short Interest	0.77M	Perf YTD	-7.69%
Book/sh	22.80	P/C	2.05	EPS next 5Y	-	ROE	0.20%	52W High	194.01 -42.11%	Perf Year	-28.48%
Cash/sh	54.75	P/FCF	3.90	EPS past 3/5Y	-28.52% 26.83%	ROIC	0.11%	52W Low	111.85 0.42%	Perf 3Y	44.57%
Dividend Est.	-	EV/EBITDA	13.35	Sales past 3/5Y	42.31% 74.82%	Gross Margin	64.07%	Volatility	4.17% 4.25%	Perf 5Y	92.49%
Dividend TTM	-	EV/Sales	2.95	EPS Y/Y TTM	-98.41%	Oper. Margin	20.80%	ATR (14)	5.29	Perf 10Y	56060.00%
Dividend Ex-Date	Oct 31, 2012	Quick Ratio	0.96	Sales Y/Y TTM	-8.86%	Profit Margin	0.14%	RSI (14)	32.87	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.96	EPS Q/Q	-3.52%	SMA20	-8.10%	Beta	0.84	Target Price	76.00
Payout	0.00%	Debt/Eq	1.55	Sales Q/Q	-15.09%	SMA50	-12.07%	Rel Volume	1.30	Prev Close	116.40
Employees	8764	LT Debt/Eq	0.79	Earnings	Feb 09 AMC	SMA200	-25.98%	Avg Volume	97.05K	Price	112.32
IPO	Aug 12, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	125,799	Change	-3.51%

Feb-10-26 03:57AM	Freedom Holding Corp. Reports Financial Results for the Nine Months and Quarter Ended December 31, 2025 (PR Newswire)
Feb-09-26 04:45PM	Freedom Holding Corp. Reports Third Quarter Fiscal Year 2026 Financial Results (Business Wire)
Nov-22-25 01:09AM	Freedom Holding Corp Publishes 2025 Sustainability Report on ESG Initiatives (PR Newswire)
Nov-13-25 08:52AM	Freedom Holding Corp. to Sponsor the Financial Times Global Banking Summit (PR Newswire)
Nov-07-25 07:00PM	Freedom Holding Corp. Reports Financial Results for the Q2 FY2026 and 1H FY2026 (ACCESSWIRE)
04:45PM	Loading…
04:45PM	Freedom Holding Corp. Reports Second Quarter Fiscal Year 2026 Financial Results (Business Wire)
04:02PM	Freedom Holding Corp. to Build $2B Sovereign AI Hub in Kazakhstan Powered by NVIDIA (PR Newswire)
06:35AM	Nvidia Strikes $2 Billion AI Chip Deal With Kazakhstan (GuruFocus.com)
Oct-14-25 10:00AM	Freedom Holding Corp. (FRHC) Shares Included in The Motley Fool's TMF Moneyball Portfolio (GlobeNewswire)
Oct-06-25 12:34AM	LD Micro Celebrates the 2,000th Company: MDB Capital Holdings (MDBH) (Newsfile)
Sep-11-25 05:30AM	China-Kazakhstan economic, cross-border e-commerce ties to grow: Freedom Holding CEO (South China Morning Post)
Sep-03-25 02:00PM	Freedom Bank and UnionPay Business Forge Partnership to Advance Kazakhstan-China Cross-Border E-Commerce (ACCESSWIRE)
08:30AM	Freedom Capital Markets Expands Platform with New Leadership, Research Analysts, and Sales Professionals (Business Wire)
Aug-31-25 12:15PM	BlackRock Becomes the Second-Largest Shareholder of Freedom Holding Corp. (PR Newswire)
Aug-25-25 06:27PM	Road to Battlefield: Central Eurasias largest startup competition in history sends four winners to TechCrunch Startup Battlefield (TechCrunch)
05:39PM	Loading…
Aug-09-25 05:39PM	Freedom Holding Corp. reports 17% revenue growth in Q1 FY2026 driven by strong insurance and banking segments (PR Newswire)
Aug-08-25 05:01PM	Freedom Holding Corp. Reports First Quarter Fiscal Year 2026 Financial Results (Business Wire)
Aug-07-25 02:15PM	2025 FIDE World Schools Team Championship & Smart Moves Summit Have Come to a Thrilling End! The USA Team is Among the Winners! (ACCESSWIRE)
Aug-05-25 08:15AM	Day One of Smart Moves Summit 2025: Strategic Leadership and Innovation in Global Chess Education (ACCESSWIRE)
Jul-23-25 11:00AM	Freedom Holding Corp. Sponsors the 2025 FIDE World Schools Team Championship and Smart Moves Summit (ACCESSWIRE)
Jul-07-25 04:05PM	From Almaty to Stanford: Freedom Holding becomes a global business case study (etf.com)
03:00PM	First Trust Financials AlphaDEX becomes the largest shareholders of Freedom Holding after Timur Turlov (PR Newswire)
Jul-01-25 04:41PM	Road to Battlefield: Central Eurasias gateway to TechCrunch Startup Battlefield (TechCrunch)
Jun-28-25 09:58AM	Freedom Holding Corp.: S&P Global Ratings Upgrades Outlook on Key Operating Subsidiaries to "Positive" on Strengthened Risk Management and Compliance (PR Newswire)
Jun-27-25 08:00AM	S&P Revises Outlook for Freedom Holding Corp. Subsidiaries to Positive (Business Wire)
Jun-15-25 11:05AM	Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results (PR Newswire)
Jun-13-25 05:22PM	Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results (Business Wire)
May-29-25 07:00AM	Freedom Holding Corp. Announces Inclusion in Russell 3000 Index (ACCESSWIRE)
May-28-25 04:54AM	Freedom Holding Corp. To Host Investors' Day in London (PR Newswire) +6.44%
Feb-07-25 09:33AM	Freedom Holding Corp. Reports Strong Revenue Growth in Q3 2025 Fiscal Year, Driven by Brokerage and Banking Segments (GlobeNewswire) +5.31%
08:36AM	Loading…
08:36AM	Freedom Holding Corp. Reports Third Quarter Fiscal Year 2025 Financial Results (Business Wire)
Jan-14-25 12:00AM	Freedom Holding Announces Launch of New Brokerage in Turkey (ACCESSWIRE)
Jan-10-25 09:20AM	LD Micro Announces the 15th Annual Invitational Returning to New York on April 9-10, 2025 (Business Wire)
Jan-09-25 06:00AM	Freedom Holding Corp.: Chess Champions of the World (ACCESSWIRE)
Dec-16-24 07:17AM	FIDE World Rapid and Blitz Chess Championship Announces Full List of Players Competing for World Title (Business Wire)
Dec-13-24 10:00AM	Freedom Holding's Subsidiaries Earn Upgraded Credit Ratings Amidst Steady Growth and Strengthened Compliance (ACCESSWIRE)
Dec-10-24 10:00AM	Freedom Holding Corp. Presents the 2024 FIDE World Rapid and Blitz Championships in New York City (ACCESSWIRE)
10:00AM	Freedom Holding Corp. Presents the 2024 FIDE World Rapid & Blitz Championships in New York City (ACCESSWIRE)
Dec-03-24 09:07AM	Chess and Finance Conference Makes Wall Street Debut During FIDE World Rapid and Blitz Chess Championship in New York City (Business Wire)
09:07AM	Chess and Finance Conference Makes Wall Street Debut During FIDE World Rapid & Blitz Chess Championship in New York City (Business Wire)
Nov-22-24 10:21AM	FIDE World Rapid and Blitz Chess Championship Makes Historic Debut in New York City (Business Wire)
10:21AM	FIDE World Rapid & Blitz Chess Championship Makes Historic Debut in New York City (Business Wire)
Nov-12-24 11:00PM	Freedom Holding Corp. Reports Robust Financial Performance (TipRanks)
Nov-08-24 10:00PM	Freedom Holding Corp. Reports Second Quarter Fiscal Year 2025 Financial Results (ACCESSWIRE)
Aug-19-24 11:15PM	Insider Sale: CEO Robert Wotczak Sells Shares of Freedom Holding Corp (FRHC) (GuruFocus.com)
Aug-09-24 01:52PM	FRHC Stock Earnings: Freedom Holding Reported Results for Q1 2024 (InvestorPlace)
07:28AM	Freedom Holding Corp. Reports First Quarter Fiscal Year 2025 Results (Business Wire)
Jul-01-24 01:16PM	S&P Revises Outlook for Freedom Holding Corp. Subsidiaries to Positive (Business Wire)
Jun-18-24 08:30AM	LD Micro to Host the 17th Annual Main Event (News Direct)
Jun-14-24 09:53PM	FRHC Stock Earnings: Freedom Holding Reported Results for Q4 2023 (InvestorPlace) +6.04%
05:00PM	Freedom Holding Corp. Reports Fiscal Year 2024 Financial Results (ACCESSWIRE)
Jun-13-24 05:30PM	Freedom Holding Corp. Reports Fiscal Year 2024 Financial Results (Business Wire)
Jun-06-24 08:30AM	Freedom Capital Markets Appoints Edward Maguire as Senior Managing Director of the U.S. Equities Research Team (News Direct)
Jun-04-24 09:30AM	FIDE Announces Finalists for the 2024 World Corporate Chess Championship (News Direct)
Jun-03-24 10:01AM	Freedom Holding Corp. Appoints New Board Members and Announces Creation of Chief Legal Officer Position (Business Wire)
May-16-24 11:38AM	Freedom Holding Corp. to Be Title Sponsor of Landmark Chess Event in New York City (Business Wire)
Apr-01-24 07:30AM	Freedom Holding Corp. CEO, Timur Turlov, to Deliver Keynote Speech at LD Micro Inaugural New York Investor Conference (Business Wire)
Feb-12-24 09:35AM	Freedom Holding Corp. Reports Third Quarter Fiscal Year 2024 Financial Results (Business Wire)
Jan-25-24 04:00PM	Freedom Holding Corp. Announces Completion of External Review of Allegations Made in Short-Seller Report (Business Wire) +8.40%
Aug-15-23 12:54PM	Short-Seller Hindenburg Takes Aim at Freedom Holding Corp. Stock (The Wall Street Journal)
Aug-14-23 02:00PM	Freedom Holding Corp. Receives Nasdaq Notification of Noncompliance with Listing Rule 5250(c)(1) (Business Wire)
Jun-20-23 08:00AM	Freedom Holding Acquires Majority Stake in Online Supermarket Arbuz (Business Wire)
Jun-16-23 02:00PM	Freedom Holding Corp. Receives Nasdaq Notification of Noncompliance with Listing Rule 5250(c)(1) (Business Wire)
Jun-01-23 02:00PM	Freedom Holding Corp to Present at LD Micro Invitational XIII (Business Wire)
May-05-23 01:42PM	Futu Holdings Stock Trying To Close In On Key Technical Benchmark (Investor's Business Daily)
May-02-23 07:30AM	LD Micro Announces Invitational XIII and Inaugural Open Forum (Business Wire)
Apr-24-23 07:31AM	Freedom Holding Corp. Enters Into Agreement to Acquire Travel Platforms (Business Wire)
Mar-06-23 08:00AM	Freedom Holding Acquires LD Micro From SRAX, Inc. (Business Wire)
Feb-27-23 04:30PM	Freedom Holding Corp. Russian Divestiture Approved and Completed (Business Wire)
Feb-16-23 08:00AM	Freedom Holding Corp. Enters into Agreement to Acquire Investment Bank Maxim Group to Expand U.S. Presence (Business Wire) +23.90%
Nov-16-22 07:30AM	Jon V. Rogers Joins Freedom Capital Markets (Business Wire)
Oct-28-22 12:09PM	KILL Freedom Finance Europe Granted EuroCCP Membership (Business Wire)
Oct-19-22 04:59PM	Freedom Holding Corp. Enters into Agreement to Sell Russian Businesses (Business Wire)
Oct-18-22 04:30PM	Freedom Holding Corp. Appoints Deloitte (Business Wire)
Jun-20-22 11:52AM	Here's Why We Think Freedom Holding (NASDAQ:FRHC) Is Well Worth Watching (Simply Wall St.)
Apr-01-22 05:10PM	Freedom Holding and MKM Holdings Announce Mutual Termination of Acquisition (ACCESSWIRE)
Mar-17-22 02:00PM	S&P Global Ratings of Freedom Holding Corp. Subsidiaries Downgraded in Wake of Russia-Ukraine Conflict (ACCESSWIRE)
Feb-28-22 08:00AM	Freedom Holding Corp. Subsidiary Receives Approval to Acquire Insurance Companies (ACCESSWIRE)
Feb-01-22 03:01PM	Freedom Holding Corp. (FRHC) to Report Q3 Results: Wall Street Expects Earnings Growth (Zacks)
Jan-26-22 09:15AM	Freedom Holding Corp. Subsidiary, Prime Executions, Inc., Launches Capital Markets Group (ACCESSWIRE)
Jan-20-22 11:25PM	Freedom Holding Corp. Subsidiary Top Bond Underwriter in Kazakhstan (ACCESSWIRE)
Jan-10-22 08:25AM	Here's Why I Think Freedom Holding (NASDAQ:FRHC) Might Deserve Your Attention Today (Simply Wall St.)
Dec-20-21 06:25PM	Freedom Holding Corp. Garners International Recognition (ACCESSWIRE)
Dec-08-21 04:55PM	Freedom Holding Corp. Announces Expansion Plans in Kazakhstan (ACCESSWIRE)
Dec-03-21 10:00AM	Freedom Holding Corp. Agrees to Acquire MKM Partners LLC (ACCESSWIRE)
Nov-01-21 03:01PM	Freedom Holding Corp. (FRHC) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-11-21 04:00AM	Freedom Finance Europe receives direct membership in Euroclear (Business Wire)
Oct-02-21 10:17AM	Is Freedom Holding Corp. (NASDAQ:FRHC) Popular Amongst Insiders? (Simply Wall St.)
Sep-29-21 12:00PM	All You Need to Know About Freedom Holding Corp. (FRHC) Rating Upgrade to Buy (Zacks)
Aug-03-21 03:57AM	If You Like EPS Growth Then Check Out Freedom Holding (NASDAQ:FRHC) Before It's Too Late (Simply Wall St.)
Jun-25-21 02:00PM	Freedom Holding Corp. Subsidiaries' S&P Global Rating Raised (ACCESSWIRE)
May-28-21 07:00PM	Freedom Holding Corp. Announces Research Coverage by Sidoti & Company (ACCESSWIRE) +7.56%
Apr-25-21 04:59AM	Do Insiders Own Lots Of Shares In Freedom Holding Corp. (NASDAQ:FRHC)? (Simply Wall St.)
Apr-08-21 02:55PM	Freedom Holding Stock Earns A Spot On IBD 50, Nears Buy Point (Investor's Business Daily)
Feb-24-21 12:37AM	Here's Why I Think Freedom Holding (NASDAQ:FRHC) Might Deserve Your Attention Today (Simply Wall St.)
Jan-10-21 03:14AM	How Should Investors Feel About Freedom Holding's (NASDAQ:FRHC) CEO Remuneration? (Simply Wall St.)
Jan-06-21 06:00PM	Freedom Holding Corp. Completes Acquisition of Prime Executions, Inc. (ACCESSWIRE)
Dec-21-20 04:30PM	Freedom Holding Corp. Set to Acquire Prime Executions, Inc. (ACCESSWIRE) +9.80%
Dec-02-20 09:54PM	Is Freedom Holding Corp. (FRHC) A Good Stock To Buy Now? (Insider Monkey)
Nov-11-20 07:23AM	What Percentage Of Freedom Holding Corp. (NASDAQ:FRHC) Shares Do Insiders Own? (Simply Wall St.) +5.23%

Freedom Holding Corp. operates as an investment company, which provides securities brokerage and financial services. The firm engages in a range of activities including securities brokerage, securities dealing for customers, market making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It operates through the following segments: Brokerage, Banking, Insurance, and Other. The company was founded in July 1981 is headquartered in Almaty, Kazakhstan.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gamble Andrew	Director	Feb 12 '26	Sale	119.39	400	47,756	357	Feb 17 04:14 PM
Lukyanov Sergey	*See Remarks	Aug 29 '25	Buy	171.67	5,725	982,811	132,425	Sep 02 04:06 PM
Tukanov Renat	CHIEF TECHNOLOGY OFFICER	Aug 29 '25	Sale	173.25	3,006	520,791	3,000	Sep 02 04:05 PM
Yerdessov Azamat	Freedom Life Chief Exec. Ofc.	Aug 27 '25	Sale	177.00	2,007	355,239	160,493	Aug 28 04:00 PM
Yerdessov Azamat	Freedom Life Chief Exec. Ofc.	Aug 21 '25	Proposed Sale	169.25	10,000	1,692,500		Aug 21 01:09 PM
Zhumagulov Aidos	BoD Member, Freedom Bank KZ &	Jul 09 '25	Proposed Sale	144.92	29,438	4,266,155		Jul 10 07:03 AM
Lukyanov Sergey	*See Remarks	Jun 30 '25	Buy	144.05	3,800	547,390	123,600	Jul 02 04:21 PM
Lukyanov Sergey	*See Remarks	Jul 01 '25	Buy	146.64	3,100	454,584	126,700	Jul 02 04:21 PM
Tukanov Renat	CHIEF TECHNOLOGY OFFICER	Jul 01 '25	Proposed Sale	145.50	3,000	436,500		Jul 01 02:44 PM
Tashtitov Askar	President	Jun 20 '25	Buy	140.75	600	84,450	137,208	Jun 20 04:02 PM
Tukanov Renat	CHIEF TECHNOLOGY OFFICER	Mar 04 '25	Sale	143.01	3,000	429,024	6,006	Mar 06 04:04 PM
Zhumagulov Aidos	*See Remarks	Feb 28 '25	Sale	145.00	6,000	870,000	144,786	Mar 03 04:09 PM
Zhumagulov Aidos	*See Remarks	Feb 27 '25	Sale	150.00	927	139,050	150,786	Mar 03 04:09 PM
Tukanov Renat	CHIEF TECHNOLOGY OFFICER	Mar 04 '25	Proposed Sale	0.05	3,000	148		Mar 03 01:38 PM
Zhumagulov Aidos	BoD Member, Freedom Bank KZ &	Feb 28 '25	Proposed Sale	157.01	6,369	1,000,000		Feb 28 04:37 PM
Lukyanov Sergey	*See Remarks	Feb 25 '25	Sale	144.00	1,000	144,000	119,800	Feb 27 04:04 PM
Ler Evgeny	Chief Financial Officer	Feb 18 '25	Sale	157.37	15,114	2,378,518	38,794	Feb 20 05:00 PM
Ler Evgeny	Chief Financial Officer	Feb 19 '25	Sale	155.23	4,886	758,454	33,908	Feb 20 05:00 PM
Lukyanov Sergey	*See Remarks	Feb 19 '25	Sale	157.00	2,042	320,594	120,800	Feb 20 05:00 PM
Lukyanov Sergey	*See Remarks	Feb 18 '25	Sale	160.53	1,958	314,318	122,842	Feb 20 05:00 PM
Wotczak Robert	Pres & CEO - Prime Executions	Feb 18 '25	Sale	156.88	11,000	1,725,640	59,000	Feb 20 08:15 AM
Wotczak Robert	Pres & CEO - Prime Executions	Feb 19 '25	Sale	156.56	9,000	1,409,070	50,000	Feb 20 08:15 AM
Ler Evgeny	Chief Financial Officer	Feb 18 '25	Proposed Sale	157.00	20,000	3,140,000		Feb 19 01:55 PM
Wotczak Robert	Officer	Feb 18 '25	Proposed Sale	157.33	20,000	3,146,600		Feb 18 01:45 PM

Open in Screener

XOMA

XOMA Royalty Corp

Feb 17 • 04:00PM ET

24.47

+0.46 1.92 %

Healthcare • Biotechnology • USA • NASD

XOMA XOMA Royalty Corp daily Stock Chart

Peers: AMGN GILD VRTX REGN BMRN BIIB IONS INCY NBIX EXEL

| Held by: VTI IWM VXF IWO VTWO VHT IWC IWN DFAS DFAC

Index	RUT	P/E	32.82	EPS (ttm)	0.75	Insider Own	1.93%	Shs Outstand	12.31M	Perf Week	3.47%
Market Cap	303.02M	Forward P/E	36.31	EPS next Y	0.67	Insider Trans	66.78%	Shs Float	12.14M	Perf Month	-15.01%
Enterprise Value	363.00M	PEG	-	EPS next Q	-0.11	Inst Own	69.04%	Short Float	8.66%	Perf Quarter	-24.10%
Income	9.87M	P/S	6.43	EPS this Y	170.91%	Inst Trans	2.57%	Short Ratio	2.79	Perf Half Y	-22.00%
Sales	47.11M	P/B	3.43	EPS next Y	-42.39%	ROA	6.43%	Short Interest	1.05M	Perf YTD	-7.97%
Book/sh	7.14	P/C	3.29	EPS next 5Y	-	ROE	16.22%	52W High	39.92 -38.70%	Perf Year	-8.56%
Cash/sh	7.43	P/FCF	56.22	EPS past 3/5Y	- -48.78%	ROIC	4.43%	52W Low	18.35 33.34%	Perf 3Y	14.61%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-9.28% 9.17%	Gross Margin	95.13%	Volatility	4.36% 6.25%	Perf 5Y	-37.14%
Dividend TTM	-	EV/Sales	7.71	EPS Y/Y TTM	123.49%	Oper. Margin	-44.69%	ATR (14)	1.59	Perf 10Y	48.50%
Dividend Ex-Date	-	Quick Ratio	3.91	Sales Y/Y TTM	118.02%	Profit Margin	20.96%	RSI (14)	44.07	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	3.91	EPS Q/Q	144.00%	SMA20	-3.24%	Beta	0.87	Target Price	64.50
Payout	-	Debt/Eq	1.22	Sales Q/Q	29.93%	SMA50	-8.01%	Rel Volume	0.27	Prev Close	24.01
Employees	13	LT Debt/Eq	1.07	Earnings	Nov 12 BMO	SMA200	-16.99%	Avg Volume	377.44K	Price	24.47
IPO	Jun 06, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	1850.00% -18.46%	Trades		Volume	100,125	Change	1.92%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Initiated	The Benchmark Company	Buy	$35
Apr-29-24	Initiated	Leerink Partners	Outperform	$40
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral	$22
Jun-29-21	Initiated	Aegis Capital	Buy	$60
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$30 → $56
Jan-18-18	Reiterated	H.C. Wainwright	Buy	$38 → $49
Oct-17-17	Resumed	H.C. Wainwright	Buy	$38
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform	$9 → $19
Jun-12-17	Initiated	H.C. Wainwright	Buy	$15
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral	$17 → $14
Mar-11-16	Reiterated	Wedbush	Outperform	$6 → $3
Jul-23-15	Downgrade	Jefferies	Buy → Hold
Jul-22-15	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-22-15	Downgrade	Ladenburg Thalmann	Buy → Neutral
Oct-10-14	Resumed	ROTH Capital	Buy	$9
Apr-29-14	Upgrade	MLV & Co	Hold → Buy	$7
Mar-11-14	Downgrade	MLV & Co	Buy → Hold	$8 → $7
Mar-05-14	Reiterated	Ladenburg Thalmann	Buy	$6.50 → $10
Oct-31-13	Reiterated	MLV & Co	Buy	$7.50 → $8
May-09-13	Reiterated	Ladenburg Thalmann	Buy	$5 → $6

Show Previous Ratings

Feb-09-26 09:53AM	XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. (GlobeNewswire)
Jan-12-26 07:30AM	XOMA Royalty Announces CFO Transition (GlobeNewswire) -10.25%
Jan-05-26 08:48AM	Implied Volatility Surging for XOMA Royalty Stock Options (Zacks)
Dec-30-25 07:30AM	XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab (GlobeNewswire)
Dec-22-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
12:28PM	Loading…
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-11-25 06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) -22.76%
Dec-05-25 09:00AM	XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc (GlobeNewswire)
Nov-21-25 07:45AM	XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. (GlobeNewswire)
Nov-12-25 08:45AM	XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Nov-04-25 10:15AM	Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-28-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates (Zacks)
09:16AM	Loading…
Oct-20-25 09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks)
Oct-17-25 11:45AM	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement (GlobeNewswire)
Oct-02-25 04:43PM	XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. (GlobeNewswire)
Sep-24-25 06:00AM	ESSA Pharma Inc. Amends Agreement with XenoTherapeutics (PR Newswire)
Sep-23-25 02:00AM	Why Xoma, a drug royalty firm, is hunting biotech zombies (BioPharma Dive)
Sep-22-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-19-25 09:55AM	Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect? (Zacks)
Sep-17-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. (GlobeNewswire)
Sep-03-25 09:55AM	Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know (Zacks)
07:30AM	XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-01-25 09:55AM	Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-20-25 12:52PM	Xoma, a drug royalty specialist, buys another zombie biotech (BioPharma Dive)
08:49AM	Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share (GlobeNewswire)
Aug-18-25 09:55AM	How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15% (Zacks)
Aug-13-25 04:55PM	LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +8.54%
08:55AM	Loading…
08:55AM	XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:51AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-11-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics (GlobeNewswire)
Aug-07-25 05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-06-25 09:10AM	Novavax (NVAX) Q2 Earnings and Revenues Top Estimates (Zacks) -7.10%
Aug-04-25 08:15AM	Xoma strikes deals to buy struggling biotechs HilleVax, Lava (BioPharma Dive) +10.01%
07:30AM	XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right (GlobeNewswire)
07:00AM	HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right (GlobeNewswire)
Jul-14-25 08:00AM	ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction (PR Newswire)
Jul-10-25 04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jun-27-25 07:30AM	Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jun-24-25 10:38AM	XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? (Zacks) +5.23%
Jun-18-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
May-27-25 08:01AM	XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million (GlobeNewswire)
May-13-25 08:50AM	XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates (Zacks) +10.89%
07:48AM	XOMA Royalty: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements (GlobeNewswire)
May-07-25 07:30AM	XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire) +6.25%
Apr-22-25 04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-14-25 07:30AM	XOMA Royalty Completes Sale of Kinnate Pipeline Assets (GlobeNewswire)
Apr-09-25 09:45AM	XOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey) +7.62%
Apr-08-25 07:15AM	BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 (ACCESSWIRE)
12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Apr-02-25 07:30AM	XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Mar-20-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-17-25 04:30PM	XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements (GlobeNewswire)
Feb-24-25 04:05PM	XOMA Royalty to Present at Investor Conferences in March (GlobeNewswire)
Feb-04-25 07:30AM	XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-19-24 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-02-24 07:30AM	XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio (GlobeNewswire)
Nov-11-24 12:00PM	What Makes XOMA Royalty (XOMA) a New Buy Stock (Zacks)
Nov-07-24 09:00AM	XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.96%
07:52AM	XOMA Royalty: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Oct-22-24 08:00AM	XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience (GlobeNewswire)
08:00AM	Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash (Business Wire)
Sep-23-24 06:30AM	Zevra's MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
05:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-04-24 07:30AM	XOMA Royalty to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 08:45AM	XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.40%
07:39AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Jul-18-24 04:08AM	Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains? (Zacks)
Jun-21-24 07:54AM	Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock? (Zacks) -5.23%
Jun-20-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +15.64%
Jun-12-24 07:30AM	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher (GlobeNewswire)
06:00AM	3 Crazy Good Stocks to Buy With $500 Right Now (InvestorPlace)
May-14-24 07:30AM	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 03:18PM	XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss (GuruFocus.com) +7.39%
May-09-24 01:55PM	XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Xoma: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
May-07-24 10:00AM	Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-30-24 07:30AM	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% (GlobeNewswire)
Apr-25-24 07:30AM	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-03-24 09:00AM	XOMA Corporation Announces Closing of Tender Offer (GlobeNewswire)
Mar-21-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-19-24 04:05PM	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. (GlobeNewswire)
Mar-08-24 12:53PM	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:12AM	XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:52AM	Xoma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value (GlobeNewswire)
Feb-28-24 07:30AM	XOMA to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-16-24 08:00AM	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jan-18-24 08:30AM	XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition (GlobeNewswire)
Jan-11-24 04:05PM	FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx (GlobeNewswire)
Jan-08-24 07:30AM	XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors (GlobeNewswire)
Jan-02-24 07:30AM	XOMA Announces Stock Repurchase Program of up to $50 Million (GlobeNewswire) +12.92%

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hughes Owen	Chief Executive Officer	Dec 04 '25	Buy	25.05	100,000	2,505,000	102,000	Dec 08 04:30 PM
Sitko Bradley	Chief Investment Officer	Sep 19 '25	Option Exercise	0.00	6,712	0	19,822	Sep 23 05:32 PM
Hughes Owen	Chief Executive Officer	Sep 19 '25	Option Exercise	0.00	35,567	0	98,268	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 19 '25	Option Exercise	0.00	11,846	0	34,409	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 22 '25	Sale	35.99	4,330	155,820	30,079	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 19 '25	Option Exercise	0.00	3,033	0	12,134	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 10 '25	Option Exercise	0.00	9,101	0	9,101	Sep 12 04:30 PM
Sitko Bradley	Chief Investment Officer	Jun 30 '25	Buy	25.39	2,000	50,780	7,045	Jul 02 04:30 PM
Hughes Owen	Chief Executive Officer	May 19 '25	Option Exercise	0.00	53,359	0	88,338	May 21 07:11 PM
Hughes Owen	Chief Executive Officer	May 20 '25	Sale	25.38	25,637	650,667	62,701	May 21 07:11 PM
BURNS THOMAS M.	SVP, Finance & CFO	May 19 '25	Option Exercise	0.00	17,773	0	33,045	May 21 07:11 PM
BURNS THOMAS M.	SVP, Finance & CFO	May 20 '25	Sale	25.38	10,482	266,033	22,563	May 21 07:11 PM
BVF PARTNERS L P/IL	10% Owner	May 16 '25	Sale	27.10	392,723	10,642,793	1,267,545	May 20 06:56 PM
Sitko Bradley	Chief Investment Officer	Apr 07 '25	Buy	24.70	2,000	49,400	5,045	Apr 09 04:44 PM
LIMBER JOSEPH M	Director	Apr 03 '25	Buy	25.24	17,935	452,631	16,524	Apr 07 04:39 PM
LIMBER JOSEPH M	Director	Apr 04 '25	Buy	25.40	6,822	173,293	20,000	Apr 07 04:39 PM
LIMBER JOSEPH M	Director	Apr 07 '25	Buy	25.60	5,243	134,221	10,000	Apr 07 04:39 PM
Sitko Bradley	Chief Investment Officer	Mar 31 '25	Buy	21.04	1,245	26,201	11,484	Apr 02 04:30 PM
BURNS THOMAS M.	SVP, Finance & CFO	Apr 01 '25	Buy	25.46	1,000	25,460	2,000	Apr 02 04:30 PM
Sitko Bradley	Chief Investment Officer	Mar 21 '25	Buy	23.89	4,134	98,751	10,484	Mar 25 04:30 PM

Open in Screener

BCDA

BioCardia Inc

Feb 17 • 04:00PM ET

1.16

+0.02 2.19 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	30.07%	Shs Outstand	10.61M	Perf Week	-7.54%
Market Cap	12.37M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	30.31%	Shs Float	7.42M	Perf Month	-16.79%
Enterprise Value	7.72M	PEG	-	EPS next Q	-0.17	Inst Own	6.26%	Short Float	3.15%	Perf Quarter	-7.54%
Income	-8.54M	P/S	-	EPS this Y	58.62%	Inst Trans	8.66%	Short Ratio	2.93	Perf Half Y	-39.32%
Sales	0.00M	P/B	4.70	EPS next Y	31.67%	ROA	-137.58%	Short Interest	0.23M	Perf YTD	-6.80%
Book/sh	0.25	P/C	2.34	EPS next 5Y	34.77%	ROE	-317.47%	52W High	3.20 -63.59%	Perf Year	-58.98%
Cash/sh	0.50	P/FCF	-	EPS past 3/5Y	36.28% 40.58%	ROIC	-300.92%	52W Low	1.00 16.50%	Perf 3Y	-96.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-61.48% -39.41%	Gross Margin	-	Volatility	7.49% 6.95%	Perf 5Y	-98.42%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	58.50%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-99.01%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	40.90	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.62	EPS Q/Q	61.55%	SMA20	-6.07%	Beta	0.61	Target Price	15.50
Payout	-	Debt/Eq	0.24	Sales Q/Q	-	SMA50	-10.32%	Rel Volume	0.31	Prev Close	1.14
Employees	20	LT Debt/Eq	0.08	Earnings	Nov 12 AMC	SMA200	-32.55%	Avg Volume	79.72K	Price	1.16
IPO	Nov 13, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	-4.35% -	Trades		Volume	24,476	Change	2.19%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Feb-10-26 09:15AM	BioCardia Files Pre-Submission for FDA Approval of Helix Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart (GlobeNewswire)
Feb-03-26 08:00AM	BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire)
Dec-16-25 08:00AM	BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA (GlobeNewswire)
Dec-03-25 08:00AM	BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno (GlobeNewswire)
Dec-01-25 08:30AM	BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress (GlobeNewswire)
08:15AM	Loading…
Nov-24-25 08:15AM	BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality (GlobeNewswire)
Nov-12-25 04:40PM	BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Nov-10-25 08:30AM	BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Nov-05-25 07:29PM	BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 (GlobeNewswire)
Oct-30-25 08:00AM	BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Oct-02-25 08:00AM	BioCardia Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-22-25 08:00AM	BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Sep-18-25 09:15AM	BioCardia Announces Pricing of Up To $12 Million Public Offering (GlobeNewswire) -23.78%
07:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up (GlobeNewswire)
Sep-04-25 09:00AM	BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 (GlobeNewswire)
08:00AM	Loading…
Aug-13-25 08:00AM	BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology (GlobeNewswire) +6.90%
Aug-11-25 09:15AM	BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.15%
Aug-06-25 03:18PM	BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 (GlobeNewswire) -5.52%
Aug-04-25 06:00AM	BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter (GlobeNewswire) -7.98%
Jul-24-25 09:00AM	BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure (GlobeNewswire)
Jul-16-25 08:45AM	Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Jun-25-25 08:00AM	BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
05:45AM	Loading…
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and Avance Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Feb 04 '26	Buy	1.13	5,000	5,650	273,866	Feb 04 05:47 PM
Altman Peter	President and CEO	Jan 20 '26	Buy	1.32	600	792	268,566	Jan 21 05:03 PM
Altman Peter	President and CEO	Jan 21 '26	Buy	1.34	300	402	268,866	Jan 21 05:03 PM
Altman Peter	President and CEO	Dec 17 '25	Buy	1.30	900	1,170	267,966	Dec 17 06:32 PM
Altman Peter	President and CEO	Dec 16 '25	Buy	1.37	200	274	267,066	Dec 17 06:32 PM
STERTZER SIMON H	Director	Sep 19 '25	Buy	1.25	398,400	498,000	591,054	Sep 23 09:00 AM
Blank Andrew Scott	Director	Sep 19 '25	Buy	1.25	288,000	360,000	634,023	Sep 23 09:00 AM
Altman Peter	President and CEO	Sep 19 '25	Buy	1.25	48,000	60,000	216,762	Sep 23 09:00 AM
Altman Peter	President and CEO	Aug 22 '25	Buy	1.83	700	1,281	168,762	Aug 25 09:30 AM
Altman Peter	President and CEO	Aug 13 '25	Buy	1.83	100	183	168,062	Aug 13 06:59 PM
Altman Peter	President and CEO	Aug 12 '25	Buy	1.75	400	700	167,962	Aug 12 07:23 PM
Altman Peter	President and CEO	Aug 11 '25	Buy	1.76	1,700	2,989	167,562	Aug 11 07:21 PM
McClung David	Chief Financial Officer	Jun 30 '25	Buy	2.08	4,819	9,999	47,950	Jul 02 09:03 PM
Altman Peter	President and CEO	Jun 30 '25	Buy	2.08	24,096	49,999	165,862	Jul 02 09:02 PM
STERTZER SIMON H	Director	Jun 30 '25	Buy	2.08	72,289	150,000	192,654	Jul 02 09:02 PM
Blank Andrew Scott	Director	Jun 30 '25	Buy	2.08	72,289	150,000	346,023	Jul 02 09:01 PM
Altman Peter	President and CEO	May 30 '25	Buy	2.21	100	221	141,766	May 30 08:55 PM
Altman Peter	President and CEO	May 20 '25	Buy	2.08	1,600	3,328	140,966	May 22 06:45 PM
Altman Peter	President and CEO	May 22 '25	Buy	1.89	700	1,323	141,666	May 22 06:45 PM
Altman Peter	President and CEO	May 16 '25	Buy	2.43	300	730	139,366	May 16 05:31 PM
Altman Peter	President and CEO	May 14 '25	Buy	2.99	100	299	139,066	May 16 05:31 PM
KRASNO RICHARD M	Director	Apr 23 '25	Buy	1.91	13,123	24,999	16,268	Apr 28 06:46 PM
McClung David	Chief Financial Officer	Apr 23 '25	Buy	1.91	13,123	24,999	43,131	Apr 25 09:38 PM
Facteau Bill	Director	Apr 23 '25	Buy	1.91	13,123	24,999	13,123	Apr 25 09:37 PM
Blank Andrew Scott	Director	Apr 23 '25	Buy	1.91	131,233	249,999	265,957	Apr 25 09:36 PM
STERTZER SIMON H	Director	Apr 23 '25	Buy	1.91	104,986	199,998	120,365	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 23 '25	Buy	1.91	26,246	49,999	138,966	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 15 '25	Buy	2.14	100	214	112,720	Apr 17 07:44 PM
Altman Peter	President and CEO	Apr 11 '25	Buy	2.03	300	609	112,620	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 10 '25	Buy	1.99	300	597	112,320	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 07 '25	Buy	1.96	500	980	112,020	Apr 08 05:01 PM
Altman Peter	President and CEO	Apr 04 '25	Buy	2.04	800	1,632	111,520	Apr 07 05:10 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.20	600	1,320	110,720	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 02 '25	Buy	2.23	500	1,115	110,120	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.24	1,200	2,688	109,620	Apr 03 09:08 PM
STERTZER SIMON H	Director	Mar 05 '25	Buy	2.45	1,000	2,450	57,138	Mar 07 08:30 AM
STERTZER SIMON H	Director	Mar 03 '25	Buy	2.30	22,753	52,332	40,602	Mar 05 08:30 AM
STERTZER SIMON H	Director	Mar 04 '25	Buy	2.30	15,536	35,733	56,138	Mar 05 08:30 AM
Altman Peter	President and CEO	Mar 03 '25	Buy	2.11	500	1,055	108,420	Mar 04 08:30 AM

Open in Screener

EXOZ

eXoZymes Inc

Feb 17 • 04:00PM ET

10.00

-0.22 -2.18 %

Healthcare • Biotechnology • USA • NASD

Held by: VXF IWC VTI

Index	-	P/E	-	EPS (ttm)	-1.00	Insider Own	74.90%	Shs Outstand	8.39M	Perf Week	-4.08%
Market Cap	83.90M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.11M	Perf Month	-7.15%
Enterprise Value	80.12M	PEG	-	EPS next Q	-	Inst Own	0.75%	Short Float	0.47%	Perf Quarter	-39.02%
Income	-8.34M	P/S	-	EPS this Y	-	Inst Trans	0.03%	Short Ratio	2.71	Perf Half Y	3.09%
Sales	0.00M	P/B	15.61	EPS next Y	-	ROA	-147.87%	Short Interest	0.01M	Perf YTD	-8.26%
Book/sh	0.64	P/C	16.45	EPS next 5Y	-	ROE	-940.69%	52W High	22.63 -55.81%	Perf Year	-48.51%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	-81.79% -	ROIC	-130.76%	52W Low	8.86 12.87%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.84% 5.33%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.53	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.40	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	4.53	EPS Q/Q	-2.94%	SMA20	-6.60%	Beta	2.30	Target Price	-
Payout	-	Debt/Eq	0.25	Sales Q/Q	-	SMA50	-14.69%	Rel Volume	1.13	Prev Close	10.22
Employees	31	LT Debt/Eq	0.19	Earnings	-	SMA200	-17.17%	Avg Volume	3.66K	Price	10.00
IPO	Nov 13, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	4,145	Change	-2.18%

Feb-10-26 04:20PM	With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation (ACCESSWIRE)
Jan-29-26 07:45PM	eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run (ACCESSWIRE)
Dec-11-25 04:10PM	eXoZymes Achieves 100x Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion (ACCESSWIRE) -9.81%
Nov-14-25 12:07AM	EXoZymes Inc (EXOZ) Q3 2025 Earnings Call Highlights: Unlocking Market Opportunities Amid ... (GuruFocus.com) -6.95%
Nov-13-25 04:30PM	eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today (ACCESSWIRE)
04:15PM	Loading…
04:15PM	eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff (ACCESSWIRE)
Nov-10-25 05:00PM	eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST (ACCESSWIRE) +14.29% -5.12%
Oct-30-25 04:10PM	CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference (ACCESSWIRE)
Oct-29-25 05:40PM	CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference (ACCESSWIRE) +13.87%
Oct-23-25 04:50PM	CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference (ACCESSWIRE)
Oct-14-25 06:58PM	eXoZymes Inc. Partners With B2i Digital to Spotlight the Cell-Free Next Generation of Biomanufacturing (NewMediaWire)
Sep-30-25 04:10PM	Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees (ACCESSWIRE)
Aug-12-25 04:50PM	eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today (ACCESSWIRE)
Aug-07-25 06:35PM	eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST (ACCESSWIRE)
Jul-29-25 07:57AM	eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity (ACCESSWIRE)
04:10PM	Loading…
Jul-22-25 04:10PM	eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months (ACCESSWIRE)
Jun-26-25 04:10PM	eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing (ACCESSWIRE) -5.03% +6.83%
May-16-25 09:25AM	eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast (ACCESSWIRE) +10.96%
May-12-25 04:10PM	eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today (ACCESSWIRE) +16.03%
May-07-25 05:20PM	eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST (ACCESSWIRE) +13.73%
May-06-25 04:10PM	eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health (ACCESSWIRE)
Apr-21-25 04:10PM	Bringing clarity and precision to the cell-free space by introducing exozymes (GlobeNewswire) +12.61%
Apr-10-25 04:30PM	BioClick an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant (GlobeNewswire) -7.39%
Apr-02-25 04:10PM	eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO (GlobeNewswire)
04:05PM	eXoZymes Provides Fourth Quarter and Full Year 2024 Update (GlobeNewswire)
Mar-26-25 05:00PM	eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 (GlobeNewswire) -19.67%
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire)
Feb-21-25 04:05PM	eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. (GlobeNewswire)
Feb-19-25 08:25AM	eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering (GlobeNewswire)
Feb-10-25 11:00AM	Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol (GlobeNewswire)
09:05AM	Loading…
Nov-19-24 09:05AM	Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities (GlobeNewswire) +14.54%
Nov-14-24 04:05PM	Invizyne Technologies Announces Closing of Initial Public Offering (GlobeNewswire) +19.77% +7.34%
Nov-13-24 04:05PM	Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing (GlobeNewswire)
09:05AM	Invizyne Technologies Begins Trading on NASDAQ (GlobeNewswire)
Nov-12-24 10:52AM	Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024 (GlobeNewswire)

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heltzen Michael	Chief Executive Officer	Jul 02 '25	Buy	10.22	1,040	10,629	10,629	Jul 02 05:49 PM

Open in Screener

CALC

CalciMedica Inc

Feb 17 • 04:00PM ET

0.6127

-0.0424 -6.47 %

Healthcare • Biotechnology • USA • NASD

Peers: PVLA LCTX APLT COGT GALT DTIL SYBX BIVI JAGX LVTX

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.61	Insider Own	51.94%	Shs Outstand	14.26M	Perf Week	-6.14%
Market Cap	8.83M	Forward P/E	-	EPS next Y	-1.37	Insider Trans	0.68%	Shs Float	6.93M	Perf Month	-88.40%
Enterprise Value	3.65M	PEG	-	EPS next Q	-0.41	Inst Own	19.47%	Short Float	10.10%	Perf Quarter	-81.03%
Income	-23.06M	P/S	-	EPS this Y	-39.55%	Inst Trans	-13.44%	Short Ratio	0.65	Perf Half Y	-78.95%
Sales	0.00M	P/B	-	EPS next Y	19.53%	ROA	-148.18%	Short Interest	0.70M	Perf YTD	-90.70%
Book/sh	-0.02	P/C	0.63	EPS next 5Y	-14.33%	ROE	-526.36%	52W High	7.20 -91.49%	Perf Year	-75.59%
Cash/sh	0.98	P/FCF	-	EPS past 3/5Y	62.80% 47.54%	ROIC	-267.15%	52W Low	0.52 17.80%	Perf 3Y	-93.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.01% 20.28%	Perf 5Y	-99.84%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.46%	Oper. Margin	-	ATR (14)	0.39	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	20.50	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	4.04	EPS Q/Q	-2.60%	SMA20	-71.16%	Beta	0.57	Target Price	14.25
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-85.08%	Rel Volume	0.41	Prev Close	0.66
Employees	14	LT Debt/Eq	-	Earnings	Nov 12 BMO	SMA200	-79.94%	Avg Volume	1.07M	Price	0.61
IPO	Sep 25, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.06% -	Trades		Volume	439,345	Change	-6.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Downgrade	H.C. Wainwright	Buy → Neutral

Jan-29-26 07:24AM	CalciMedicas stock drops 75% on acute kidney injury trial termination (Clinical Trials Arena) -18.40%
Jan-28-26 11:48AM	CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis (Benzinga) -75.59%
07:00AM	CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation (PR Newswire)
Nov-12-25 07:01AM	CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates (PR Newswire)
07:00AM	CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension (PR Newswire)
07:00AM	Loading…
Nov-10-25 07:00AM	CalciMedica Presents Data from Preclinical Study of Auxora in an Animal Model of AKI at ASN Kidney Week 2025 (PR Newswire)
Oct-14-25 07:00AM	CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora (PR Newswire)
Sep-02-25 07:00AM	CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire) +14.81%
Aug-19-25 02:42PM	Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks (MarketBeat) -5.54%
Aug-12-25 07:00AM	CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates (PR Newswire) -10.14%
Jul-08-25 07:00AM	CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference (PR Newswire)
Jun-25-25 07:00AM	CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora in AKI with Respiratory Failure (PR Newswire)
Jun-12-25 07:00AM	CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting (PR Newswire)
May-14-25 07:00AM	CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates (PR Newswire)
Apr-17-25 07:00AM	CalciMedica Announces Presentations at Upcoming Medical Meetings (PR Newswire)
12:00PM	Loading…
Apr-02-25 12:00PM	CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade (Zacks) -5.13%
Apr-01-25 07:00AM	CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference (PR Newswire)
Mar-27-25 07:00AM	CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates (PR Newswire)
Mar-05-25 07:00AM	CalciMedica Secures Credit Facility for Up to $32.5 Million (PR Newswire) -6.17%
Mar-04-25 07:00AM	CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference (PR Newswire)
Feb-19-25 07:00AM	CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference (PR Newswire)
Feb-03-25 04:05PM	CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-14-25 07:00AM	CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors (PR Newswire)
Nov-21-24 08:00AM	CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-20-24 04:05PM	CalciMedica Announces Presentations at Upcoming Medical Meetings (PR Newswire)
Nov-13-24 07:00AM	CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates (PR Newswire)
Nov-07-24 07:00AM	CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer (PR Newswire)
Oct-30-24 10:11PM	CalciMedica Announces Pricing of Public Offering of Common Stock (PR Newswire) +22.14% -22.92%
04:50PM	CalciMedica Announces Proposed Public Offering of Common Stock (PR Newswire)
07:00AM	CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting (PR Newswire)
04:05PM	Loading…
Oct-28-24 04:05PM	CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) (PR Newswire)
Oct-16-24 08:00AM	CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting (PR Newswire)
Sep-03-24 08:00AM	CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +7.67%
Aug-12-24 04:10PM	CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates (PR Newswire)
Jul-09-24 07:30AM	CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora in Severe Acute Kidney Injury (AKI) (PR Newswire)
Jul-08-24 08:00AM	CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences (PR Newswire)
Jul-01-24 08:00AM	CalciMedica Set to Join Russell Microcap Index (PR Newswire) +7.32%
Jun-27-24 08:00AM	CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) (PR Newswire) -32.40%
07:06AM	CalciMedica's calcium channel inhibitor helps subgroup of pancreatitis patients eat solids sooner (FierceBiotech.com)
Jun-26-24 04:05PM	CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) (PR Newswire) -10.04%
May-28-24 07:53AM	CALC Stock Earnings: CalciMedica Beats EPS for Q1 2024 (InvestorPlace)
May-21-24 09:48AM	3 Massively Undervalued 10-Bagger Stocks to Buy (InvestorPlace)
May-13-24 04:05PM	CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates (PR Newswire) -7.14% +6.73%
May-07-24 08:00AM	CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024 (PR Newswire)
Apr-24-24 08:00AM	CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (PR Newswire) +19.61%
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
Mar-28-24 11:53AM	CALC Stock Earnings: CalciMedica Reported Results for Q4 2023 (InvestorPlace)
07:00AM	CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates (PR Newswire)
Mar-13-24 08:00AM	CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference (PR Newswire)
Feb-28-24 06:57PM	CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference (PR Newswire)
Feb-13-24 08:00AM	CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora for the Treatment of Severe Acute Kidney Injury (PR Newswire) -8.21%
Feb-07-24 04:05PM	CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire) +6.92% -9.99%
Jan-22-24 08:00AM	CalciMedica Announces Private Placement of up to Approximately $55 Million (PR Newswire) +7.09%
Dec-11-23 07:30AM	CalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition (PR Newswire) -13.88%
Nov-09-23 07:00AM	CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates (PR Newswire) -12.74%
Nov-02-23 09:15AM	CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition (PR Newswire) +10.23%
Sep-06-23 07:30AM	CalciMedica Announces Upcoming Presentations and Events in September (PR Newswire) +5.18%
Aug-31-23 07:30AM	CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023 (PR Newswire)
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
Aug-10-23 04:05PM	CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates (GlobeNewswire)
06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research)
Aug-09-23 07:30AM	CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora in Acute Pancreatitis (AP) (GlobeNewswire) +6.06%
06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research)
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research)
Aug-02-23 07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research)
Aug-01-23 06:51AM	Daily Vickers Top Insider Picks for 08/01/2023 (Argus Research) -6.29%
Jul-31-23 06:44AM	Daily Vickers Top Insider Picks for 07/31/2023 (Argus Research)
Jul-28-23 07:58AM	Daily Vickers Top Insider Picks for 07/28/2023 (Argus Research)
Jul-27-23 07:10AM	Daily Vickers Top Insider Picks for 07/27/2023 (Argus Research)
Jul-26-23 01:12PM	Daily Vickers Top Insider Picks for 07/26/2023 (Argus Research)
Jul-25-23 07:16AM	Daily Vickers Top Insider Picks for 07/25/2023 (Argus Research) -6.11%
Jul-24-23 07:12AM	Daily Vickers Top Insider Picks for 07/24/2023 (Argus Research)
Jul-21-23 07:23AM	Daily Vickers Top Insider Picks for 07/21/2023 (Argus Research)
Jul-20-23 06:55AM	Daily Vickers Top Insider Picks for 07/20/2023 (Argus Research)
Jul-19-23 07:10AM	Daily Vickers Top Insider Picks for 07/19/2023 (Argus Research)
Jul-18-23 06:53AM	Daily Vickers Top Insider Picks for 07/18/2023 (Argus Research) -5.56%
Jul-17-23 07:10AM	Daily Vickers Top Insider Picks for 07/17/2023 (Argus Research) +5.16%
Jul-14-23 06:50AM	Daily Vickers Top Insider Picks for 07/14/2023 (Argus Research)
Jul-13-23 07:02AM	Daily Vickers Top Insider Picks for 07/13/2023 (Argus Research)
Jul-12-23 07:22AM	Daily Vickers Top Insider Picks for 07/12/2023 (Argus Research) +7.08%
Jul-11-23 06:08AM	Daily Vickers Top Insider Picks for 07/11/2023 (Argus Research)
Jul-10-23 06:56AM	Daily Vickers Top Insider Picks for 07/10/2023 (Argus Research)
Jul-05-23 06:46AM	Daily Vickers Top Insider Picks for 07/05/2023 (Argus Research) +13.07%
Jul-03-23 06:50AM	Daily Vickers Top Insider Picks for 07/03/2023 (Argus Research)
Jun-30-23 06:52AM	Daily Vickers Top Insider Picks for 06/30/2023 (Argus Research) -17.32%
Jun-29-23 06:49AM	Daily Vickers Top Insider Picks for 06/29/2023 (Argus Research) +11.75%
Jun-28-23 06:58AM	Daily Vickers Top Insider Picks for 06/28/2023 (Argus Research)
Jun-27-23 06:46AM	Daily Vickers Top Insider Picks for 06/27/2023 (Argus Research) +28.00%
Jun-26-23 06:41AM	Daily Vickers Top Insider Picks for 06/26/2023 (Argus Research)
Jun-23-23 09:24AM	Daily Vickers Top Insider Picks for 06/23/2023 (Argus Research) -6.76%
Jun-12-23 07:30AM	CalciMedica Announces Relisting on Nasdaq (GlobeNewswire)
Jun-06-23 07:30AM	CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP) (GlobeNewswire) +16.85%
May-23-23 07:30AM	CalciMedica Expands Executive Team with New Appointments (GlobeNewswire) +9.49%
May-15-23 08:55AM	CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates (GlobeNewswire)
Mar-29-23 07:53PM	Charts Point to Higher Highs, Says Oppenheimer. Heres a Stock With Over 100% Upside Potential (TipRanks) -8.76% -29.60%

CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts Eric W	CHIEF BUSINESS OFFICER	Sep 18 '25	Buy	3.07	2,500	7,675	84,150	Sep 22 09:35 AM
Roberts Eric W	CHIEF BUSINESS OFFICER	Sep 15 '25	Buy	2.68	3,400	9,105	81,650	Sep 17 09:45 AM
Roberts Eric W	CHIEF BUSINESS OFFICER	Sep 12 '25	Buy	3.12	5,000	15,600	78,250	Sep 15 12:31 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Sep 09 '25	Buy	3.15	2,343	7,378	73,250	Sep 11 12:00 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Aug 28 '25	Buy	2.86	9,200	26,340	70,107	Sep 02 01:05 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Aug 29 '25	Buy	2.74	800	2,192	70,907	Sep 02 01:05 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Aug 21 '25	Buy	2.79	3,508	9,797	60,907	Aug 25 09:30 AM
Roberts Eric W	CHIEF BUSINESS OFFICER	Aug 20 '25	Option Exercise	1.53	15,000	22,950	179,706	Aug 21 12:00 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Aug 20 '25	Buy	2.72	2,000	5,440	57,399	Aug 21 12:00 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Aug 19 '25	Buy	2.79	1,000	2,790	55,399	Aug 21 12:00 PM
Hebbar Sudarshan	Chief Medical Officer	Aug 19 '25	Buy	2.82	9,563	26,962	61,539	Aug 21 12:00 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Aug 15 '25	Buy	2.90	5,076	14,709	54,399	Aug 19 01:45 PM
Hebbar Sudarshan	Chief Medical Officer	Aug 15 '25	Buy	2.79	4,392	12,267	51,976	Aug 18 12:00 PM
Hebbar Sudarshan	Chief Medical Officer	Aug 14 '25	Buy	2.58	1,584	4,095	47,584	Aug 18 12:00 PM
Stauderman Kenneth A.	Chief Scientific Officer	Jul 28 '25	Buy	3.96	1,000	3,960	12,944	Jul 29 04:52 PM
Stauderman Kenneth A.	Chief Scientific Officer	Jul 25 '25	Sale	3.65	1,000	3,650	0	Jul 29 04:52 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jul 22 '25	Buy	3.77	1,500	5,662	49,323	Jul 23 11:55 AM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jul 21 '25	Buy	3.37	1,500	5,055	47,823	Jul 22 12:15 PM
Leheny A. Rachel	CHIEF EXECUTIVE OFFICER	Jul 21 '25	Buy	3.40	1,000	3,400	3,500	Jul 21 02:02 PM
WILSON ROBERT N	Director	Jul 18 '25	Buy	2.87	4,500	12,915	422,029	Jul 18 02:42 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jul 18 '25	Buy	2.88	2,000	5,760	46,323	Jul 18 02:36 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jul 14 '25	Buy	2.43	6,500	15,810	44,323	Jul 16 12:58 PM
Leheny A. Rachel	CHIEF EXECUTIVE OFFICER	Jul 14 '25	Buy	2.47	2,500	6,175	2,500	Jul 15 09:29 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jul 09 '25	Buy	1.60	5,000	8,024	37,823	Jul 10 08:18 PM
Stauderman Kenneth A.	Chief Scientific Officer	Jul 01 '25	Buy	1.85	1,000	1,850	1,000	Jul 02 09:48 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jun 26 '25	Buy	1.44	4,500	6,483	32,823	Jun 27 07:35 PM
Bardin Stephen	Chief Financial Officer	Jun 26 '25	Buy	1.50	2,000	3,005	3,000	Jun 26 06:30 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jun 11 '25	Buy	1.85	5,000	9,250	28,323	Jun 13 05:05 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jun 06 '25	Buy	1.77	5,000	8,875	23,323	Jun 09 04:08 PM
Roberts Eric W	CHIEF BUSINESS OFFICER	Jun 05 '25	Buy	1.70	5,100	8,670	18,323	Jun 09 04:08 PM
Bardin Stephen	Chief Financial Officer	May 30 '25	Buy	1.69	1,000	1,690	41,000	Jun 03 05:10 PM

Open in Screener

AUBN

Auburn National Bancorp Inc

Feb 17 • 04:00PM ET

25.00

0.00 0.00 %

Financial • Banks - Regional • USA • NASD

AUBN Auburn National Bancorp Inc daily Stock Chart

Peers: SRCE FFNW GSBC BHB LKFN MCHB INDB NBTB CATY HTLF

| Held by: VTI VXF BSVO IWC DFAC DFAT DFUS DCOR DFAS DXUV

Index	-	P/E	12.04	EPS (ttm)	2.08	Insider Own	29.89%	Shs Outstand	3.49M	Perf Week	1.54%
Market Cap	88.74M	Forward P/E	-	EPS next Y	-	Insider Trans	0.13%	Shs Float	2.45M	Perf Month	2.84%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	12.61%	Short Float	0.16%	Perf Quarter	-1.96%
Income	7.25M	P/S	2.15	EPS this Y	-	Inst Trans	2.81%	Short Ratio	1.62	Perf Half Y	-3.40%
Sales	41.22M	P/B	0.95	EPS next Y	-	ROA	0.73%	Short Interest	0.00M	Perf YTD	-7.24%
Book/sh	26.35	P/C	-	EPS next 5Y	-	ROE	8.52%	52W High	29.00 -13.79%	Perf Year	18.54%
Cash/sh	-	P/FCF	8.84	EPS past 3/5Y	-11.02% -0.14%	ROIC	8.10%	52W Low	19.00 31.58%	Perf 3Y	3.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-0.02% -0.47%	Gross Margin	-	Volatility	0.82% 1.93%	Perf 5Y	-35.67%
Dividend TTM	1.08 (4.32%)	EV/Sales	-	EPS Y/Y TTM	13.41%	Oper. Margin	22.35%	ATR (14)	0.73	Perf 10Y	-1.92%
Dividend Ex-Date	Mar 10, 2026	Quick Ratio	-	Sales Y/Y TTM	-2.35%	Profit Margin	17.60%	RSI (14)	47.40	Recom	-
Dividend Gr. 3/5Y	0.63% 1.15%	Current Ratio	0.22	EPS Q/Q	6.65%	SMA20	-1.12%	Beta	0.43	Target Price	-
Payout	52.03%	Debt/Eq	0.00	Sales Q/Q	-21.64%	SMA50	-2.44%	Rel Volume	0.51	Prev Close	25.00
Employees	145	LT Debt/Eq	0.00	Earnings	-	SMA200	2.95%	Avg Volume	2.34K	Price	25.00
IPO	Aug 03, 1995	Option/Short	No / Yes	EPS/Sales Surpr.	58.00% -3.09%	Trades		Volume	1,187	Change	0.00%

Feb-10-26 03:15PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jan-27-26 08:17AM	Auburn National: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports Fourth Quarter and Full Year Results (GlobeNewswire)
Nov-12-25 02:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Oct-23-25 04:39PM	Auburn National: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	Loading…
04:30PM	Auburn National Bancorporation, Inc. Reports Third Quarter Net Earnings (GlobeNewswire)
Oct-06-25 04:30PM	Auburn National Bancorporation, Inc. Elects New Director (GlobeNewswire)
Aug-12-25 12:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jul-22-25 08:12AM	Auburn National: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports Second Quarter Net Earnings (GlobeNewswire)
May-13-25 06:30PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Apr-22-25 08:09AM	Auburn National: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports First Quarter Net Earnings (GlobeNewswire)
Apr-02-25 03:32PM	Auburn National Bancorporation, Inc. (AUBN): Insider Were Buying In Q1 2025 (Insider Monkey)
Feb-11-25 01:05PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
08:16AM	Loading…
Jan-28-25 08:16AM	Auburn National: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports Fourth Quarter and Full Year Results (GlobeNewswire)
Nov-12-24 01:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Oct-22-24 08:34AM	Auburn National: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports Third Quarter Net Earnings (GlobeNewswire)
Aug-13-24 04:20PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jul-23-24 08:11AM	Auburn National: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports Second Quarter Net Earnings (GlobeNewswire)
May-14-24 06:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Apr-29-24 03:00PM	Insider Buying: President & CEO David Hedges Acquires Shares of Auburn National Bancorp Inc ... (GuruFocus.com) +6.05%
Apr-24-24 08:10AM	Auburn National: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports First Quarter Net Earnings (GlobeNewswire)
Mar-29-24 11:39AM	Auburn National Bancorporation, Inc. Elects Two New Directors (GlobeNewswire)
Feb-13-24 04:20PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jan-29-24 04:40PM	Auburn National: Q4 Earnings Snapshot (Associated Press Finance)
04:30PM	Loading…
04:30PM	Auburn National Bancorporation, Inc. Reports Fourth Quarter and Full Year Results (GlobeNewswire)
Dec-13-23 09:45AM	12 Best Micro-Cap Dividend Stocks To Buy Now (Insider Monkey)
Nov-22-23 02:58PM	3 Stocks With Dividend Yields Over 5% (InvestorPlace)
Nov-14-23 04:45PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Oct-26-23 06:50PM	Auburn National Bancorp Inc (AUBN) Reports Q3 2023 Earnings (GuruFocus.com)
05:18PM	Auburn National: Q3 Earnings Snapshot (Associated Press Finance)
05:00PM	Auburn National Bancorporation, Inc. Reports Third Quarter Net Earnings (GlobeNewswire)
Aug-12-23 08:02AM	Auburn National Bancorporation (NASDAQ:AUBN) Will Pay A Dividend Of $0.27 (Simply Wall St.)
Aug-08-23 04:05PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Aug-07-23 08:05PM	Southern States Bank, AuburnBank report quarterly growth (American City Business Journals)
Jul-25-23 08:10AM	Auburn National: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Auburn National Bancorporation, Inc. Reports Second Quarter Net Earnings (GlobeNewswire)
Jun-03-23 08:37AM	Why You Might Be Interested In Auburn National Bancorporation, Inc. (NASDAQ:AUBN) For Its Upcoming Dividend (Simply Wall St.)
Jun-01-23 02:47PM	Auburn National Bancorporation's (NASDAQ:AUBN) Dividend Will Be $0.27 (Simply Wall St.)
May-15-23 06:02AM	Auburn National Bancorporation (NASDAQ:AUBN) Is Paying Out A Dividend Of $0.27 (Simply Wall St.)
May-10-23 08:00AM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Apr-25-23 08:17AM	Auburn National: Q1 Earnings Snapshot (AP Finance)
08:05AM	Auburn National Bancorporation, Inc. Reports First Quarter Net Earnings (GlobeNewswire)
Mar-04-23 07:49AM	Is It Smart To Buy Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Before It Goes Ex-Dividend? (Simply Wall St.)
Feb-19-23 07:11AM	Auburn National Bancorporation's (NASDAQ:AUBN) Shareholders Will Receive A Bigger Dividend Than Last Year (Simply Wall St.)
Feb-14-23 05:25PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Feb-01-23 05:32AM	Auburn National Bancorporation Full Year 2022 Earnings: EPS: US$2.95 (vs US$2.27 in FY 2021) (Simply Wall St.)
Jan-30-23 08:00AM	Auburn National Bancorporation, Inc. Reports Record Full Year Net Earnings of $10.3 million, or $2.95 per share and Record Quarterly Net Earnings of $4.5 million, or $1.27 per share (GlobeNewswire)
Nov-12-22 07:12AM	Auburn National Bancorporation (NASDAQ:AUBN) Has Announced A Dividend Of $0.265 (Simply Wall St.)
Nov-08-22 01:05PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
12:18PM	Auburn National Bancorporation, Inc. Announces Leadership Succession Plan (GlobeNewswire)
Oct-25-22 08:00AM	Auburn National Bancorporation, Inc. Reports Third Quarter Net Earnings (GlobeNewswire)
Aug-13-22 08:27AM	Auburn National Bancorporation (NASDAQ:AUBN) Will Pay A Dividend Of $0.265 (Simply Wall St.)
Aug-11-22 07:30AM	The past three years for Auburn National Bancorporation (NASDAQ:AUBN) investors has not been profitable (Simply Wall St.)
Aug-09-22 12:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jul-26-22 08:00AM	Auburn National Bancorporation, Inc. Reports Second Quarter Net Earnings (GlobeNewswire)
Jun-05-22 09:04AM	Be Sure To Check Out Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Before It Goes Ex-Dividend (Simply Wall St.)
May-13-22 03:20PM	Do Institutions Own Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Shares? (Simply Wall St.)
May-11-22 04:30PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Apr-26-22 08:05AM	Auburn National Bancorporation, Inc. Reports First Quarter Net Earnings (GlobeNewswire)
Apr-12-22 04:15PM	Auburn National Bancorporation Authorizes Stock Repurchase Program (GlobeNewswire)
Feb-12-22 06:04AM	Auburn National Bancorporation (NASDAQ:AUBN) Will Pay A Larger Dividend Than Last Year At US$0.27 (Simply Wall St.)
Feb-08-22 04:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jan-27-22 08:00AM	Auburn National Bancorporation, Inc. Reports Full Year Net Earnings of $8.0 million, or $2.27 per share; Quarterly Net Earnings of $1.9 million, or $0.53 per share (GlobeNewswire)
Jan-24-22 12:35PM	10 Best Dividend Contenders to Buy for 2022 (Insider Monkey)
Dec-04-21 06:14AM	Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Looks Like A Good Stock, And It's Going Ex-Dividend Soon (Simply Wall St.)
Nov-14-21 06:11AM	Auburn National Bancorporation's (NASDAQ:AUBN) Dividend Will Be US$0.26 (Simply Wall St.)
Nov-09-21 12:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Oct-19-21 08:00AM	Auburn National Bancorporation, Inc. Reports Third Quarter Net Earnings (GlobeNewswire)
Sep-05-21 08:09AM	Auburn National Bancorporation (NASDAQ:AUBN) Will Pay A Dividend Of US$0.26 (Simply Wall St.)
Sep-04-21 08:22AM	Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Looks Interesting, And It's About To Pay A Dividend (Simply Wall St.)
Sep-02-21 06:39AM	The past three years for Auburn National Bancorporation (NASDAQ:AUBN) investors has not been profitable (Simply Wall St.)
Aug-10-21 11:05AM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jul-20-21 08:00AM	Auburn National Bancorporation, Inc. Reports Second Quarter Net Earnings (GlobeNewswire)
Jun-04-21 01:31AM	Auburn National Bancorporation's (NASDAQ:AUBN) Dividend Will Be US$0.26 (Simply Wall St.)
May-11-21 05:45PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
May-05-21 01:09AM	Should Shareholders Reconsider Auburn National Bancorporation, Inc.'s (NASDAQ:AUBN) CEO Compensation Package? (Simply Wall St.)
May-02-21 03:42AM	How Much Of Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Do Insiders Own? (Simply Wall St.)
Apr-27-21 08:00AM	Auburn National Bancorporation, Inc. Reports First Quarter Net Earnings (GlobeNewswire)
Mar-09-21 04:15PM	Auburn National Bancorporation Authorizes Stock Repurchase Program (GlobeNewswire)
Feb-09-21 03:35PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jan-31-21 11:41PM	Shareholders Of Auburn National Bancorporation (NASDAQ:AUBN) Must Be Happy With Their 69% Return (Simply Wall St.)
Jan-29-21 08:30AM	Auburn National Bancorporation, Inc. Reports Full Year Net Earnings of $7.5 million, or $2.09 per share; Quarterly Net Earnings of $2.1 million, or $0.58 per share (GlobeNewswire)
Nov-10-20 11:00AM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Nov-03-20 05:32AM	How Much Is Auburn National Bancorporation's (NASDAQ:AUBN) CEO Getting Paid? (Simply Wall St.)
Oct-30-20 08:15AM	Auburn National Bancorporation, Inc. Reports Third Quarter Net Earnings (GlobeNewswire)
Sep-04-20 06:14AM	Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Looks Interesting, And It's About To Pay A Dividend (Simply Wall St.)
Aug-11-20 12:00PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire)
Jul-30-20 08:00AM	Auburn National Bancorporation, Inc. Reports Second Quarter Net Earnings (GlobeNewswire)
Jul-26-20 10:46AM	What Percentage Of Auburn National Bancorporation, Inc. (NASDAQ:AUBN) Shares Do Insiders Own? (Simply Wall St.)
Jul-01-20 03:57PM	5 Banks Outperforming the Market (GuruFocus.com)
May-27-20 06:02AM	How Does Auburn National Bancorporation's (NASDAQ:AUBN) P/E Compare To Its Industry, After Its Big Share Price Gain? (Simply Wall St.)
May-22-20 10:46AM	How to Play the Rebalancing of the Russell Indexes (Barrons.com)
May-12-20 05:45PM	Auburn National Bancorporation, Inc. Declares Quarterly Dividend (GlobeNewswire) -5.21% +7.10%
May-08-20 08:00AM	Auburn National Bancorporation, Inc. Reports First Quarter Net Earnings (GlobeNewswire)

Auburn National Bancorporation, Inc. is a bank holding company. It engages in the provision of banking services to commercial and retail customers. The firm operates through the following segments: Commercial and Industrial, Construction and Land Development, Commercial Real Estate, Residential Real Estate, and Consumer Installment. The Commercial and Industrial segment includes loans to finance business operations, equipment purchases, or other needs for small and medium-sized commercial customers. The Construction and Land Development segment is comprised of both loans and credit lines for the purpose of purchasing, carrying and developing land into commercial developments or residential subdivisions. The Commercial and Industrial segment provides loans disaggregated into three classes: owner occupied, multi-family and other. The Residential Real Estate segment is involved in consumer mortgage and investment property. The Consumer Installment segment encompasses loans to individuals both secured by personal property and unsecured. The company was founded in 1990 and is headquartered in Auburn, AL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Conn Walton T Jr.	Director	Jan 29 '26	Buy	25.17	175	4,405	850	Jan 30 04:42 PM
Conn Walton T Jr.	Director	Jan 29 '26	Buy	25.00	100	2,500	1,450	Jan 30 04:42 PM
O'DONNELL SHANNON	Senior Vice President	Jan 14 '26	Buy	27.09	27	732	1,564	Jan 15 01:05 PM
HAM WILLIAM F JR	Director	Jan 14 '26	Buy	27.08	55	1,489	5,273	Jan 15 12:47 PM
HOUSEL DAVID E	Director	Jan 14 '26	Buy	27.09	51	1,381	9,056	Jan 15 12:33 PM
Barrett J Tutt	Director	Jan 14 '26	Buy	27.09	72	1,950	9,116	Jan 15 12:27 PM
HOUSEL DAVID E	Director	Dec 03 '25	Buy	24.99	100	2,499	9,005	Dec 03 06:06 PM
HOUSEL DAVID E	Director	Dec 03 '25	Buy	24.17	25	604	8,905	Dec 03 12:56 PM
Conn Walton T Jr.	Director	Dec 01 '25	Buy	24.75	200	4,950	1,337	Dec 01 05:40 PM
HOUSEL DAVID E	Director	Nov 18 '25	Buy	25.39	200	5,078	8,880	Nov 18 03:54 PM
HAM WILLIAM F JR	Director	Oct 08 '25	Buy	27.47	54	1,484	4,918	Oct 09 11:48 AM
O'DONNELL SHANNON	Senior Vice President	Oct 08 '25	Buy	27.46	25	686	1,537	Oct 09 11:17 AM
HOUSEL DAVID E	Director	Oct 08 '25	Buy	27.47	49	1,346	8,680	Oct 09 11:09 AM
Barrett J Tutt	Director	Oct 08 '25	Buy	27.46	70	1,923	9,044	Oct 09 11:05 AM
HOUSEL DAVID E	Director	Sep 09 '25	Buy	27.19	100	2,719	8,631	Sep 09 06:26 PM
O'DONNELL SHANNON	Senior Vice President	Jul 02 '25	Buy	24.06	30	722	1,512	Jul 02 03:35 PM
HOUSEL DAVID E	Director	Jul 02 '25	Buy	24.24	55	1,333	8,531	Jul 02 03:30 PM
HAM WILLIAM F JR	Director	Jul 02 '25	Buy	24.42	60	1,465	4,864	Jul 02 03:27 PM
Barrett J Tutt	Director	Jul 02 '25	Buy	24.21	79	1,912	8,974	Jul 02 03:23 PM
HOUSEL DAVID E	Director	May 01 '25	Buy	19.77	90	1,779	8,476	May 01 06:02 PM
Walker William James IV	SVP/CFO	Apr 29 '25	Buy	19.91	100	1,991	400	Apr 29 10:20 AM
Hedges David A	President\CEO	Apr 28 '25	Buy	19.88	150	2,982	13,010	Apr 28 01:11 PM
Lawler Michael A	Director	Apr 28 '25	Buy	19.89	1,000	19,893	3,000	Apr 28 01:05 PM
HOUSEL DAVID E	Director	Apr 25 '25	Buy	19.86	200	3,972	8,386	Apr 25 04:30 PM
O'DONNELL SHANNON	Senior Vice President	Apr 02 '25	Buy	21.52	32	689	1,482	Apr 02 02:11 PM
HOUSEL DAVID E	Director	Apr 02 '25	Buy	21.53	61	1,314	8,186	Apr 02 02:05 PM
HAM WILLIAM F JR	Director	Apr 02 '25	Buy	21.54	67	1,443	4,804	Apr 02 01:48 PM
Barrett J Tutt	Director	Apr 02 '25	Buy	21.53	87	1,873	8,895	Apr 02 01:42 PM

FRHC

Freedom Holding Corp

XOMA

XOMA Royalty Corp

BCDA

BioCardia Inc

EXOZ

eXoZymes Inc

CALC

CalciMedica Inc

AUBN

Auburn National Bancorp Inc

Upgrade your FINVIZ experience